We are addressing the current challenges of CRISPR-Cas systems such as in vivo delivery and expanding the scope of disease applications by applying our proprietary discovery and engineering platform to identify novel Cas proteins and associated technologies.
Our protein discovery and engineering process starts with an in-silico analysis from one of the largest and growing metagenomic databases (including exclusive sample data) using proprietary AI algorithms to search for novel CRISPR systems and technologies. High-throughput wet-lab screening is then used to identify protein characteristics and function followed by high throughput engineering to realize our technology’s full potential. Together, the newly identified Cas proteins and associated technologies create a diverse and growing portfolio that enables new CRISPR applications to meet unmet patient needs.
We have identified Cas enzymes and associated technologies that have the ability to perform a variety of edit types as well as have unique properties including ultracompact size, increased temperature stability, faster reaction kinetics, and alternative PAM sequences for more flexible targeting.
These properties can be leveraged to realize the full potential of genetic medicine to perform a wide variety of edits in-vivo for potentially curative therapies that address major unmet patient needs.
Our ultracompact CRISPR-Cas enzymes provide a scaffold to expand beyond double-stranded breaks in vivo.
Ultracompact versions of CRISPR that make double stranded breaks to inactivate genes
A platform technology that uses epigenetic modifications to silence genes
A platform technology that makes a single-letter change to convert A to G or C to T
A platform technology that makes versatile RNA-encoded insertions, deletions or substitutions
Partnerships
Mammoth is committed to advancing science internally and through collaborations in the service of its mission to discover, develop and commercialize drugs to improve the lives of patients. Please get in touch with us below if you would like to join us on our journey.